Predictive Oncology Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a POAI research report →
About the company
Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline.
- CEO
- Raymond F. Vennare
- IPO
- 2010
- Employees
- 23
- HQ
- Pittsburgh, MN, US
Price Chart
- Market Cap
- $3.57M
- P/E
- -0.63
- P/S
- 477.80
- P/B
- 3.72
- EV/EBITDA
- -0.08
- Div Yield
- 0.00%
- Gross Margin
- -325.17%
- Op Margin
- -58805.87%
- Net Margin
- -474020.63%
- ROE
- -10705.18%
- ROIC
- -70.91%
- Revenue
- $125.28K · -92.28%
- Net Income
- $-233,095,203 · -1810.42%
- EPS
- $-13.37 · -496.87%
- Op Income
- $-28,425,165
- FCF YoY
- 16.77%
- 52W High
- $45.90
- 52W Low
- $1.21
- 50D MA
- $8.42
- 200D MA
- $13.27
- Beta
- 1.35
- Avg Volume
- 141.65K
Get TickerSpark's AI analysis on POAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Blacher Joshua | other | 9,389 |
Our POAI coverage
Recent articles, reports, and earnings notes.
No research on POAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate POAI report →Similar companies
Peers in the same neighborhood.